Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Syntaxin has selected SynCo Bio Partners as its manufacturing partner of novel drug candidate SXN101959 for the therapeutic treatment of Acromegaly as a primary indication.
Subscribe to our email newsletter
SynCo Bio Partners is a biopharmaceutical GMP Contract Manufacturing Organization licensed for clinical and commercial GMP manufacturing of Bulk Drug Substances and Drug Products.
As per the agreement, SynCo will help Syntaxin in manufacturing bulk drug substance and drug product of SXN101959 for non-clinical, Phase-I and Phase-II clinical trials.
Syntaxin CEO Melanie Lee said SynCo’s manufacturing capability provides them with the means to move SXN101959 through to Phase-I clinical trials in Acromegaly.
"Progress of SXN101959 towards the clinic follows a recent announcement that our partnered molecule AGN-214868, has entered phase-II clinical trials in post-herpetic neuralgia (PHN) as a primary indication," Lee said.